Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureShiyan He, Xiong Zeng, Jing Lin
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21660 · 2021
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21660 · 2021
Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors
10.1097/cej.0000000000000428 · 2018
Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors
10.1097/cej.0000000000000428 · 2018
Goals and targets for personalized therapy for HCC
10.1007/s12072-018-9919-1 · 2019
Goals and targets for personalized therapy for HCC
10.1007/s12072-018-9919-1 · 2019
Addressing the worldwide hepatocellular carcinoma: Epidemiology, prevention and management
10.21037/jgo.2020.02.08 · 2021
Addressing the worldwide hepatocellular carcinoma: Epidemiology, prevention and management
10.21037/jgo.2020.02.08 · 2021
A global view of hepatocellular carcinoma: trends, risk, prevention and management
10.1038/s41575-019-0186-y · 2019
A global view of hepatocellular carcinoma: trends, risk, prevention and management
10.1038/s41575-019-0186-y · 2019
Hepatitis B Virus DNA integration drives carcinogenesis and provides a new biomarker for HBV-related HCC
10.1016/j.jcmgh.2023.01.001 · 2023
Hepatitis B Virus DNA integration drives carcinogenesis and provides a new biomarker for HBV-related HCC
10.1016/j.jcmgh.2023.01.001 · 2023
Prognostic MicroRNA Panel for HCV-Associated HCC: Integrating computational biology and clinical validation
10.3390/cancers14133036 · 2022
Prognostic MicroRNA Panel for HCV-Associated HCC: Integrating computational biology and clinical validation
10.3390/cancers14133036 · 2022
From NASH to HCC: Current concepts and future challenges
10.1038/s41575-019-0145-7 · 2019
From NASH to HCC: Current concepts and future challenges
10.1038/s41575-019-0145-7 · 2019
Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis
10.1002/hep4.2045 · 2022
Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis
10.1002/hep4.2045 · 2022
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
10.1038/s41586-019-0987-8 · 2019
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
10.1038/s41586-019-0987-8 · 2019
The trends in death of primary liver cancer caused by specific etiologies worldwide: Results from the Global Burden of Disease Study 2019 and implications for liver cancer management
10.1186/s12885-023-11038-3 · 2023
The trends in death of primary liver cancer caused by specific etiologies worldwide: Results from the Global Burden of Disease Study 2019 and implications for liver cancer management
10.1186/s12885-023-11038-3 · 2023
New advances in the diagnosis and management of hepatocellular carcinoma
10.1136/bmj.m3544 · 2020
New advances in the diagnosis and management of hepatocellular carcinoma
10.1136/bmj.m3544 · 2020
The mortality and overall survival trends of primary liver cancer in the United States
10.1093/jnci/djab079 · 2021
The mortality and overall survival trends of primary liver cancer in the United States
10.1093/jnci/djab079 · 2021
Exosomes: Isolation, characterization, and biomedical applications
10.1002/cbin.11620 · 2021
Exosomes: Isolation, characterization, and biomedical applications
10.1002/cbin.11620 · 2021
Exosomal miR-4800-3p aggravates the progression of hepatocellular carcinoma via regulating the hippo signaling pathway by targeting STK25
10.3389/fonc.2022.759864 · 2022
Exosomal miR-4800-3p aggravates the progression of hepatocellular carcinoma via regulating the hippo signaling pathway by targeting STK25
10.3389/fonc.2022.759864 · 2022
Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts
10.1038/s41419-022-04506-4 · 2022
Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts
10.1038/s41419-022-04506-4 · 2022
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma
10.1186/s12943-023-01759-1 · 2023
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma
10.1186/s12943-023-01759-1 · 2023
Exosomal miR-125b exerts anti-metastatic properties and predicts early metastasis of hepatocellular carcinoma
10.3389/fonc.2021.637247 · 2021
Exosomal miR-125b exerts anti-metastatic properties and predicts early metastasis of hepatocellular carcinoma
10.3389/fonc.2021.637247 · 2021
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International society for extracellular vesicles and update of the MISEV2014 guidelines
10.1080/20013078.2018.1535750 · 2018
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International society for extracellular vesicles and update of the MISEV2014 guidelines
10.1080/20013078.2018.1535750 · 2018
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
10.1002/jev2.12404 · 2024
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
10.1002/jev2.12404 · 2024
Extracellular vesicle analysis
10.1038/s43586-023-00240-z · doi-reference
EV-TRACK: Transparent reporting and centralizing knowledge in extracellular vesicle research
10.1038/nmeth.4185 · doi-reference
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer
10.1038/s41467-017-02583-0 · doi-reference
LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma
10.1038/s41374-022-00731-9 · doi-reference
Exosome-derived SNHG16 sponging miR-4500 activates HUVEC angiogenesis by targeting GALNT1 via PI3K/Akt/mTOR pathway in hepatocellular carcinoma
10.1007/s13105-021-00833-w · doi-reference
Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma
10.1186/s12943-020-01222-5 · doi-reference
Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets
10.1038/nrgastro.2017.71 · doi-reference
Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization
10.1038/s41596-019-0126-x · doi-reference
Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation
10.1038/s41556-018-0040-4 · doi-reference
The potential of serum exosomal hsa_circ_0028861 as the novel diagnostic biomarker of HBV-derived hepatocellular cancer
10.3389/fgene.2021.703205 · doi-reference
Exosomal microRNA-4661-5p-based serum panel as a potential diagnostic biomarker for early-stage hepatocellular carcinoma
10.1002/cam4.3230 · doi-reference
Developing blood extracellular vesicle protein biomarkers for hepatocellular carcinoma: mechanisms, methods, and translation
10.1186/s12951-026-04463-6 · doi-reference
Role of extracellular vesicle-associated proteins in the progression, diagnosis, and treatment of hepatocellular carcinoma
10.1186/s13578-024-01294-6 · doi-reference
Exosomal PD-L1 in hepatocellular carcinoma: Immune evasion mechanisms, diagnostic value, and strategies for therapeutic targeting
10.1016/j.biopha.2026.119268 · doi-reference
Exosomal carboxypeptidase E (CPE) and CPE-shRNA-Loaded exosomes regulate metastatic phenotype of tumor cells
10.3390/ijms23063113 · doi-reference
Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3
10.1038/s41392-021-00579-3 · doi-reference
Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion
10.1186/s40425-018-0451-6 · doi-reference
Exosome-derived GTF2H2 from Huh7 cells can inhibit endothelial cell viability, migration, tube formation, and permeability
10.1016/j.tice.2022.101922 · doi-reference
MIRLET7BHG promotes hepatocellular carcinoma progression by activating hepatic stellate cells through exosomal SMO to trigger Hedgehog pathway
10.1038/s41419-021-03494-1 · doi-reference
Overexpressed proteins in HCC cell-derived exosomes, CCT8, and cofilin-1 are potential biomarkers for patients with HCC
10.3390/diagnostics11071221 · doi-reference
Serum-derived exosomal proteins as potential candidate biomarkers for hepatocellular carcinoma
10.1021/acsomega.0c05408 · doi-reference
The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer
10.1038/s12276-022-00855-4 · doi-reference
Advances and challenges of exosome-derived noncoding RNAs for hepatocellular carcinoma diagnosis and treatment
10.1016/j.bbrep.2024.101695 · doi-reference
Exosomal LINC00161 promotes angiogenesis and metastasis via regulating miR-590-3p/ROCK axis in hepatocellular carcinoma
10.1038/s41417-020-00269-2 · doi-reference
Exosomal lncRNA TUG1 from cancer-associated fibroblasts promotes liver cancer cell migration, invasion, and glycolysis by regulating the miR-524-5p/SIX1 axis
10.1186/s11658-022-00309-9 · doi-reference
Exosomal ZFPM2-AS1 contributes to tumorigenesis, metastasis, stemness, macrophage polarization, and infiltration in hepatocellular carcinoma through PKM mediated glycolysis
10.1002/tox.23767 · doi-reference
Tumor associated macrophages-derived exosomes facilitate hepatocellular carcinoma malignance by transferring lncMMPA to tumor cells and activating glycolysis pathway
10.1186/s13046-022-02458-3 · doi-reference
lncRNAfunc: A knowledgebase of lncRNA function in human cancer
10.1093/nar/gkab1035 · doi-reference
Tumor immune microenvironment lncRNAs
10.1093/bib/bbab504 · doi-reference
LNCcation: lncRNA localization and function
10.1083/jcb.202009045 · doi-reference
Integrated lncRNA function upon genomic and epigenomic regulation
10.1016/j.molcel.2022.05.027 · doi-reference
An emerging research: the role of hepatocellular carcinoma-derived exosomal circRNAs in the immune microenvironment
10.3389/fimmu.2023.1227150 · doi-reference
CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ
10.1186/s13046-022-02494-z · doi-reference
Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
10.1186/s13045-021-01207-x · doi-reference
Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles
10.1016/j.canlet.2021.08.037 · doi-reference
Tumor-associated macrophages in liver cancer: From mechanisms to therapy
10.1002/cac2.12345 · doi-reference
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
10.3389/fimmu.2023.1133308 · doi-reference
Immunotherapies for hepatocellular carcinoma
10.1038/s41571-021-00573-2 · doi-reference
Circular RNA hsa_circ_0004277 stimulates malignant phenotype of hepatocellular carcinoma and epithelial-mesenchymal transition of peripheral cells
10.3389/fcell.2020.585565 · doi-reference
Exosome-transmitted circ_MMP2 promotes hepatocellular carcinoma metastasis by upregulating MMP2
10.1002/1878-0261.12637 · doi-reference